nach oben

Erschienen in:

01.03.2013 | Original article

Xerostomia after radiotherapy

What matters—mean total dose or dose to each parotid gland?

verfasst von: S. Tribius, M.D., J. Sommer, C. Prosch, A. Bajrovic, A. Muenscher, M. Blessmann, A. Kruell, C. Petersen, M. Todorovic, P. Tennstedt

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Xerostomia is a debilitating side effect of radiotherapy in patients with head and neck cancer. We undertook a prospective study of the effect on xerostomia and outcomes of sparing one or both parotid glands during radiotherapy for patients with squamous cell carcinoma of the head and neck.

Methods and materials

Patients with locally advanced squamous cell carcinoma of the head and neck received definitive (70 Gy in 2 Gy fractions) or adjuvant (60–66 Gy in 2 Gy fractions) curative-intent radiotherapy using helical tomotherapy with concurrent chemotherapy if appropriate. Group A received < 26 Gy to the left and right parotids and group B received < 26 Gy to either parotid.

Results

The study included 126 patients; 114 (55 in group A and 59 in group B) had follow-up data. There were no statistically significant differences between groups in disease stage. Xerostomia was significantly reduced in group A vs. group B (p = 0.0381). Patients in group A also had significantly less dysphagia. Relapse-free and overall survival were not compromised in group A: 2-year relapse-free survival was 86% vs. 72% in group B (p = 0.361); 2-year overall survival was 88% and 76%, respectively (p = 0.251).

Conclusion

This analysis suggests that reducing radiotherapy doses to both parotid glands to < 26 Gy can reduce xerostomia and dysphagia significantly without compromising survival. Sparing both parotids while maintaining target volume coverage and clinical outcome should be the treatment goal and reporting radiotherapy doses delivered to the individual parotids should be standard practice.

Bernier J, Domenge C, Ozsahin M et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952PubMedCrossRef

Brotherston DC, Poon I, Le T et al (2012) Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck doi 10.1002/hed.22930

Chencharick JD, Mossman KL (1983) Nutritional consequences of the radiotherapy of head and neck cancer. Cancer 51:811–815PubMedCrossRef

Dijkema T, Raaijmakers CP, Ten Haken RK et al (2010) Parotid gland function after radiotherapy: the combined Michigan and Utrecht experience. Int J Radiat Oncol Biol Phys 78:449–453PubMedCrossRef

Dreyer JO, Sakuma Y, Seifert G (1989) Radiation-induced sialadenitis. Stage classification and immunohistology. Pathologe 10:165–170 (in German)PubMed

Eisbruch A, Ten Haken RK, Kim HM et al (1999) Volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45:577–587PubMedCrossRef

Fakhrian K, Thamm R, Knapp S et al (2012) Radio(chemo)therapy in the management of squamous cell carcinoma of cervical lymph nodes from an unknown primary site. A retrospective analysis. Strahlenther Onkol 188:56–61PubMedCrossRef

García-Peris P, Parón L, Velasco C et al (2007) Long-term prevalence of oropharyngeal dysphagia in head and neck cancer patients: impact on quality of life. Clin Nutr 26:710–717PubMedCrossRef

Kam MK, Leung SF, Zee B et al (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25:4873–4879PubMedCrossRef

10.

Konings AW, Coppes RP, Vissink A (2005) On the mechanism of salivary gland radiosensitivity. Int J Radiat Oncol Biol Phys 62:1187–1194PubMedCrossRef

11.

Kreppel M, Drebber U, Eich HT et al (2011) Combined-modality treatment in advanced oral squamous cell carcinoma: primary surgery followed by adjuvant concomitant radiochemotherapy. Strahlenther Onkol 187:555–560PubMedCrossRef

12.

Lee NY, Arruda FF de, Puri DR et al (2006) A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:966–974PubMedCrossRef

13.

Marur S, D’Souza G, Westra WH et al (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789PubMedCrossRef

14.

Maurer J, Hipp M, Schäfer C, Kölbl O (2011) Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer. Strahlenther Onkol 187:744–749PubMedCrossRef

15.

Murthy V, Master Z, Gupta T et al (2010) Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT. J Cancer Res Ther 6:194–198PubMedCrossRef

16.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (2011) Head and Neck Cancers version 2.2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 07 January 2013

17.

Nutting CM, Morden JP, Harrington KJ et al (2011) PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127–136PubMedCrossRef

18.

Pow EH, Kwong DL, McMillan AS et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981–991PubMedCrossRef

19.

Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRef

20.

Rades D, Ulbricht T, Hakim SG, Schild SE (2012) Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity. Strahlenther Onkol 188:42–48PubMedCrossRef

21.

Ringash J, Warde P, Lockwood G et al (2005) Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys 61:1403–1407PubMedCrossRef

22.

Roesink JM, Schipper M, Busschers W et al (2005) A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. Int J Radiat Oncol Biol Phys 63:1006–1009PubMedCrossRef

23.

Semrau R, Temming S, Preuss SF et al (2011) Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel: a phase II study. Strahlenther Onkol 187:645–650PubMedCrossRef

24.

Tribius S, Ihloff AS, Rieckmann T et al (2011) Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 304:71–79PubMedCrossRef

25.

Vergeer MR, Doornaert PA, Rietveld DH et al (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74:1–8PubMedCrossRef

26.

Vissink A, Jansma J, Spijkervet FK et al (2003) Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14:199–212PubMedCrossRef

Titel: Xerostomia after radiotherapy
What matters—mean total dose or dose to each parotid gland?
verfasst von: S. Tribius, M.D.
J. Sommer
C. Prosch
A. Bajrovic
A. Muenscher
M. Blessmann
A. Kruell
C. Petersen
M. Todorovic
P. Tennstedt
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0257-2

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Xerostomia after radiotherapy

What matters—mean total dose or dose to each parotid gland?